AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, D. D. M.
Right arrow Articles by Barker, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, D. D. M.
Right arrow Articles by Barker, P. B.

PEDIATRICS

Proton MR Spectroscopy in the Diagnostic Evaluation of Suspected Mitochondrial Disease

Doris D. M. Lina, Thomas O. Crawfordb and Peter B. Barkera

a Russel H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD
b Department of Neurology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD

Address reprint requests to Doris D.M. Lin, MD, Johns Hopkins University School of Medicine, Department of Radiology and Radiological Science, 600 N. Wolfe Street, Baltimore, MD 21287

PURPOSE AND BACKGROUND: Mitochondrial diseases are a group of inherited disorders caused by a derangement of mitochondrial respiration. The clinical manifestations are heterogeneous, and the diagnosis is often based on information acquired from multiple levels of inquiry. MR spectroscopy has previously been shown to help detect an abnormal accumulation of lactate in brain parenchyma and CSF in association with mitochondrial disorders, but the frequency of detection is largely unknown. We sought to examine the frequency of detectable elevations of CNS lactate by proton MR spectroscopy in a population of children and young adults with suspected mitochondrial disease.

METHODS: MR spectroscopy data evaluated for the presence or absence of abnormal brain or CSF lactate were compared with other clinical indicators of mitochondrial dysfunction for 29 patients with suspected mitochondrial disease during the years 1990 to 2000. Based on an independent review of the final diagnoses, the patients were divided into groups based on the probability of mitochondrial disorder.

RESULTS: A total of 32 scans from 29 patients were reviewed. Of eight patients thought to have a definitive mitochondrial disorder on the basis of genetic, biochemical, or pathologic features, five were found to have abnormal brain or CSF lactate levels revealed by MR spectroscopy (for one patient in whom two images were acquired, one was negative and the other positive). Among the studies conducted using a multisection spectroscopic imaging technique, five of six showed elevated lactate in the brain parenchyma, six of six showed elevated lactate in the CSF, and five of six showed elevated lactate in both brain and CSF. Of 16 patients who were highly suspected of having mitochondrial disorders on the basis of clinical grounds alone but who were lacking genetic, biochemical, or pathologic confirmation, four had abnormal lactate levels shown by MR spectroscopy. Mitochondrial disorder was excluded for five patients, none of whom had CNS lactate shown by MR spectroscopy.

CONCLUSION: Detection of CNS lactate by MR spectroscopy is useful in the diagnosis of mitochondrial disease. In our series of patients with confirmed mitochondrial disease, a high level of lactate shown by MR spectroscopy correlated well with other markers of mitochondrial disease. As with all other means used to diagnose mitochondrial disorders, MR spectroscopy does not depict elevated lactate in all cases. Abnormal CNS concentrations of lactate may be undetected by MR spectroscopy because of differences in the type of mitochondrial disorder, timing, severity, or location of the affected tissues and the site of interrogation.




This article has been cited by other articles:


Home page
PediatricsHome page
R. H. Haas, S. Parikh, M. J. Falk, R. P. Saneto, N. I. Wolf, N. Darin, and B. H. Cohen
Mitochondrial Disease: A Practical Approach for Primary Care Physicians
Pediatrics, December 1, 2007; 120(6): 1326 - 1333.
[Abstract] [Full Text] [PDF]


Home page
CephalalgiaHome page
P. Sandor, U Dydak, J Schoenen, S. Kollias, K Hess, P Boesiger, and R. Agosti
MR-Spectroscopic Imaging during Visual Stimulation in Subgroups of Migraine with Aura
Cephalalgia, July 1, 2005; 25(7): 507 - 518.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
T. Otsuki, T. Kanamatsu, Y. Tsukada, Y. Goto, K. Okamoto, and H. Watanabe
Carbon 13-Labeled Magnetic Resonance Spectroscopy Observation of Cerebral Glucose Metabolism: Metabolism in MELAS: Case Report
Arch Neurol, March 1, 2005; 62(3): 485 - 487.
[Abstract] [Full Text] [PDF]


Home page
J Child NeurolHome page
P. B. Barker and A. Horska
Topical Review: Neuroimaging in Leukodystrophies
J Child Neurol, August 1, 2004; 19(8): 559 - 570.
[Abstract] [PDF]


Home page
Arch Gen PsychiatryHome page
S. R. Dager, S. D. Friedman, A. Parow, C. Demopulos, A. L. Stoll, I. K. Lyoo, D. L. Dunner, and P. F. Renshaw
Brain Metabolic Alterations in Medication-Free Patients With Bipolar Disorder
Arch Gen Psychiatry, May 1, 2004; 61(5): 450 - 458.
[Abstract] [Full Text] [PDF]